Genmab receives patent for HuMax-HepC
Genmab A/S announced that a patent has been issued for HuMax®-HepC by the US Patent and Trademark Office. HuMax-HepC is a fully human antibody currently in pre-clinical development to prevent reinfection with the hepatitis C Virus (HCV) after liver transplantation. HuMax-HepC binds to a common site on diverse strains of the virus. In pre-clinical studies, the antibody prevented the HCV from attaching to susceptible cells.
"The issuance of the HuMax-HepC patent marks another important milestone in building our business," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "The patent provides broad protection over this unique antibody and gives us a potential edge over other biotech companies competing in the same arena."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.